Literature DB >> 1494511

The differing predictive values of oestrogen receptor assays for large breast cancers.

D J Gaskell1, R A Hawkins, A L Tesdale, K Sangster, U Chetty, A P Forrest.   

Abstract

Thirty elderly patients with T3 or T4 breast cancer underwent a wedge biopsy for radioligand-binding assay (RLA) of oestrogen receptor (ER) activity. A second, separate group of 21 elderly patients with T3 and T4 breast cancers underwent fine needle aspiration biopsy (FNA) for immunocytochemical assay of ER (ER-ICA). All the women received tamoxifen as primary treatment and response was assessed by UICC criteria. Tumour ER concentration by RLA was correlated with both response (Spearman's R = + 0.52) and time to progression (R = + 0.76). Nine patients with receptor-rich tumours (> 100 fmol/mg protein) failed to show a response. However, the percentage of cells staining for ER by ER-ICA assay was much more strongly related to the likelihood of response (R = + 0.89); no patient with < 20% cells staining responded. Wedge biopsy and the biochemical determination of ER activity is of limited value in predicting the likely response to tamoxifen; ER-ICA assays on such tumours may be more informative.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1494511      PMCID: PMC2399488          DOI: 10.1136/pgmj.68.805.900

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  13 in total

1.  Breast cancer in elderly women: a Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. The Elderly Breast Cancer Working Party.

Authors:  T Bates; D L Riley; J Houghton; L Fallowfield; M Baum
Journal:  Br J Surg       Date:  1991-05       Impact factor: 6.939

2.  A simple method for the determination of oestrogen receptor concentrations in breast tumours and other tissues.

Authors:  R A Hawkins; A Hill; B Freedman
Journal:  Clin Chim Acta       Date:  1975-10-15       Impact factor: 3.786

3.  Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only.

Authors:  J M Horobin; P E Preece; J A Dewar; R A Wood; A Cuschieri
Journal:  Br J Surg       Date:  1991-02       Impact factor: 6.939

4.  Primary systemic therapy for breast cancer.

Authors:  A P Forrest; E D Anderson; D Gaskill
Journal:  Br Med Bull       Date:  1991-04       Impact factor: 4.291

5.  Receptors in the management of breast cancer.

Authors:  R A Hawkins
Journal:  Br J Hosp Med       Date:  1985-09

6.  ERICA predicts response to tamoxifen in elderly women with breast cancer.

Authors:  N Davies; G Moir; R Carpenter; A Cuthbert; A Herbert; G T Royle; I Taylor
Journal:  Ann R Coll Surg Engl       Date:  1991-11       Impact factor: 1.891

7.  Oestrogen receptor concentration in primary breast cancer and axillary node metastases.

Authors:  R A Hawkins; R Black; R J Steele; J M Dixon; A P Forrest
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

8.  Prognostic value of estrogen receptors in primary breast cancer.

Authors:  R Hähnel; T Woodings; A B Vivian
Journal:  Cancer       Date:  1979-08       Impact factor: 6.860

9.  The cytochemical detection of oestrogen receptors in fine needle aspirates of breast cancer; correlation with biochemical assay and prediction of response to endocrine therapy.

Authors:  R A Hawkins; K Sangster; A Tesdale; P A Levack; E D Anderson; U Chetty; A P Forrest
Journal:  Br J Cancer       Date:  1988-07       Impact factor: 7.640

10.  Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer.

Authors:  E D Anderson; A P Forrest; P A Levack; U Chetty; R A Hawkins
Journal:  Br J Cancer       Date:  1989-08       Impact factor: 7.640

View more
  1 in total

1.  Organochlorine exposures influence on breast cancer risk and survival according to estrogen receptor status: a Danish cohort-nested case-control study.

Authors:  A P Høyer; T Jørgensen; F Rank; P Grandjean
Journal:  BMC Cancer       Date:  2001-07-30       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.